Quince Therapeutics Announced Online Publication Of Data In Lancet Neurology From Its Phase 3 ATTeST Trial Of Its Lead Asset, Erydex (Dexamethasone Sodium Phosphate Encapsulated In Autologous Erythrocytes), For Ataxia-Telangiectasia
Quince Therapeutics Announced Online Publication Of Data In Lancet Neurology From Its Phase 3 ATTeST Trial Of Its Lead Asset, Erydex (Dexamethasone Sodium Phosphate Encapsulated In Autologous Erythrocytes), For Ataxia-Telangiectasia
Quince Therapeutics宣布其主力资产Erydex（磷酸地塞米松封装在自体红细胞中）在小脑萎缩毛细血管扩张症(AT) 的3期ATTeSt试验中数据在柳叶刀神经病学期刊上在线发表。
- Findings from largest completed study in A-T demonstrated favorable safety profile
- Study showed positive effect of EryDex treatment in a subset of patients with A-T ages six to nine – the age range that typically experiences rapid clinical decline
- Quince recently initiated pivotal Phase 3 NEAT study, which is currently enrolling and being conducted under U.S. FDA Special Protocol Assessment agreement
- 最大的A-t研究结果表明，安全性表现良好。
- 研究显示，EryDex治疗可对年龄在6至9岁之间的A-t患者的一个亚组产生积极效果——这个年龄区间通常会经历急剧临床恶化。
- Quince最近启动了关键的第3阶段NEAt研究，该研究目前正在招募患者并根据美国FDA特殊协议评估协议进行。
资讯热榜
更新时间